

# Niemann-Pick Disease Type C (NPC) - Epidemiology Forecast to 2027

<https://marketpublishers.com/r/N3A5713F1F7EN.html>

Date: October 2018

Pages: 76

Price: US\$ 3,250.00 (Single User License)

ID: N3A5713F1F7EN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's 'Niemann-Pick Disease Type C (NPC) - Epidemiology Forecast to 2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Niemann-Pick Disease Type C (NPC) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

## GEOGRAPHY COVERED

The United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2027

## Niemann-Pick Disease Type C (NPC) Epidemiology

The Niemann-Pick Disease Type C (NPC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Niemann-Pick Disease Type C (NPC) are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

## Niemann-Pick Disease Type C (NPC) Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, diagnosed cases, sub-type specific (NPC1 and NPC 2) cases and clinical distribution by phenotypes] in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total prevalent population of NPC was found to be 2,099 in the year 2016 in 7MM.

### **REPORT SCOPE**

The report covers detailed overview of Niemann-Pick Disease Type C (NPC) explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns

The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

The Report assesses the disease risk and burden and highlights the unmet needs of Niemann-Pick Disease Type C (NPC)

The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population

The report provides the segmentation of the disease epidemiology by total prevalent patient population, diagnosed population, sub-types and clinical distribution in 7MM

### **KEY STRENGTHS**

10 Year Forecast of Niemann-Pick Disease Type C (NPC) epidemiology

7MM Coverage

Total Prevalent Cases of Niemann-Pick Disease Type C (NPC)

Prevalent Cases according to segmentation: Sub-type specific prevalence (NPC-1 and NPC-2), and prevalence based upon clinical distribution (early infantile, late infantile, juvenile and adult).

## **KEY ASSESSMENTS**

Patient Segmentation

Disease Risk & Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

## Contents

### 1. KEY INSIGHTS

### 2. DISEASE BACKGROUND AND OVERVIEW: NIEMANN-PICK DISEASE TYPE C (NPC)

#### 2.1. Introduction

#### 2.2. Classification of Niemann Pick Disease

#### 2.3. Causes

#### 2.4. Inheritance patterns

#### 2.5. Clinical Manifestations

#### 2.6. Pathophysiology

#### 2.7. Diagnosis

##### 2.7.1. NP-C Diagnostic Recommendations Expert Panel: Diagnostic Recommendations (2016)

##### 2.7.2. NP-C suspicion index Tool

### 3. EPIDEMIOLOGY AND PATIENT POPULATION

#### 3.1. Key Findings

#### 3.2. 7MM Total Prevalent Patient Population of Niemann Pick Disease Type-C

### 4. COUNTRY WISE-EPIDEMIOLOGY OF NPC

#### 4.1. United States

##### 4.1.1. Total Prevalent Patient Population of NPC in the United States

##### 4.1.2. Sub-type Specific Prevalence of NPC in the United States

##### 4.1.3. Diagnosed Population of NPC in the United States

##### 4.1.4. Clinical Distribution of NPC by Phenotypes

#### 4.2. EU5 Countries

#### 4.3. Germany

##### 4.3.1. Total Prevalent Patient Population of NPC in Germany

##### 4.3.2. Sub-type Specific Prevalence of NPC in Germany

##### 4.3.3. Diagnosed Population of NPC in Germany

##### 4.3.4. Clinical Distribution of NPC by Phenotypes

#### 4.4. France

##### 4.4.1. Total Prevalent Patient Population of NPC in France

##### 4.4.2. Sub-type Specific Prevalence of NPC in France

- 4.4.3. Diagnosed Population of NPC in France
- 4.4.4. Clinical Distribution of NPC by Phenotypes
- 4.5. Italy
  - 4.5.1. Total Prevalent Patient Population of NPC in Italy
  - 4.5.2. Sub-type Specific Prevalence of NPC in Italy
  - 4.5.3. Diagnosed Population of NPC in Italy
  - 4.5.4. Clinical Distribution of NPC by Phenotypes
- 4.6. Spain
  - 4.6.1. Total Prevalent Patient Population of NPC in Spain
  - 4.6.2. Sub-type Specific Prevalence of NPC in Spain
  - 4.6.3. Diagnosed Population of NPC in Spain
  - 4.6.4. Clinical Distribution of NPC by Phenotypes
- 4.7. United Kingdom
  - 4.7.1. Total Prevalent Patient Population of NPC in the UK
  - 4.7.2. Sub-type Specific Prevalence of NPC in the UK
  - 4.7.3. Diagnosed Population of NPC in the UK
  - 4.7.4. Clinical Distribution of NPC by Phenotypes
- 4.8. Japan
  - 4.8.1. Total Prevalent Patient Population of NPC in Japan
  - 4.8.2. Sub-type Specific Prevalence of NPC in Japan
  - 4.8.3. Diagnosed Population of NPC in Japan
  - 4.8.4. Clinical Distribution of NPC by Phenotypes

## **5. APPENDIX**

- 5.1. Report Methodology

## **6. DELVEINSIGHT CAPABILITIES**

## **7. DISCLAIMER**

## **8. ABOUT DELVEINSIGHT**

## List Of Tables

### LIST OF TABLES

- Table 1: Classification of signs and symptoms in NPC
- Table 2: Sign and symptom combination strongly suggestive of NPC
- Table 3: Cell biology diagnostic techniques in NPC
- Table 4: Primary and urinary diagnostic biomarkers in NPC
- Table 5: Clinical patient groups with an increased risk of Niemann-Pick Disease Type C
- Table 6: Diagnosis
- Table 7: Recommendations for diagnosis of patients identified by molecular genetic screening for NPC1 and NPC2
- Table 8: NPC suspicion index tool: Signs and symptoms
- Table 9: Total Prevalent Patient Population of NPC in 7MM (2016-2027)
- Table 10: Total Prevalent Population of NPC in the United States (2016-2027)
- Table 11: Sub-type Specific Prevalence of NPC in the United States (2016-2027)
- Table 12: Diagnosed Population of NPC in the United States (2016-2027)
- Table 13: Clinical distribution of NPC by Phenotypes of NPC in the United States (2016-2027)
- Table 14: Total Prevalent Population of NPC in Germany (2016-2027)
- Table 15: Sub-type Specific Prevalence of NPC in Germany (2016-2027)
- Table 16: Diagnosed Population of NPC in Germany (2016-2027)
- Table 17: Clinical distribution of NPC by Phenotypes in Germany (2016-2027)
- Table 18: Total Prevalent Population of NPC in France (2016-2027)
- Table 19: Sub-type Specific Prevalence of NPC in France (2016-2027)
- Table 20: Diagnosed Population of NPC in France (2016-2027)
- Table 21: Clinical distribution of NPC by Phenotypes in France (2016-2027)
- Table 22: Total Prevalent Population of NPC in Italy (2016-2027)
- Table 23: Sub-type Specific Prevalence of NPC in Italy (2016-2027)
- Table 24: Diagnosed Population of NPC in Italy (2016-2027)
- Table 25: Clinical distribution of NPC by Phenotypes in Italy (2016-2027)
- Table 26: Total Prevalent Population of NPC in Spain (2016-2027)
- Table 27: Sub-type Specific Prevalence of NPC in Spain (2016-2027)
- Table 28: Diagnosed Population of NPC in Spain (2016-2027)
- Table 29: Clinical distribution of NPC by Phenotypes in Spain (2016-2027)
- Table 30: Total Prevalent Population of NPC in the UK (2016-2027)
- Table 31: Sub-type Specific Prevalence of NPC in the UK (2016-2027)
- Table 32: Diagnosed Population of NPC in the UK (2016-2027)
- Table 33: Clinical distribution of NPC by Phenotypes in the UK (2016-2027)

Table 34: Total Prevalent Population of NPC in Japan (2016-2027)

Table 35: Sub-type Specific Prevalence of NPC in Japan (2016-2027)

Table 36: Diagnosed Population of NPC in Japan (2016-2027)

Table 37: Clinical distribution of NPC by Phenotypes in Japan (2016-2027)

## List Of Figures

### LIST OF FIGURES

- Figure 1: Classification of Niemann Pick Disease
- Figure 2: Classification of Niemann-Pick Disease Type C
- Figure 3: Inheritance Pattern of Niemann-Pick Disease Type C (NPC)
- Figure 4: Manifestations of Niemann-Pick Disease Type C (NP-C) by age group
- Figure 5: Schematic representation of Niemann-Pick Disease Type C
- Figure 6: Pathophysiology of Niemann-Pick Disease Type C 1 Disease
- Figure 7: Pathophysiology of Niemann-Pick Disease Type C 2 Disease
- Figure 8: Diagnostic Algorithm for Niemann-Pick Disease Type C
- Figure 9: Total Prevalent Patient Population of NPC in 7MM (2016-2027)
- Figure 10: Prevalence of NPC in the United States (2016-2027)
- Figure 11: Sub-type Specific Prevalence of NPC in the United States (2016-2027)
- Figure 12: Diagnosed Population of NPC in the United States (2016-2027)
- Figure 13: Clinical distribution of NPC by Phenotypes in the United States (2016-2027)
- Figure 14: Total Prevalent Population of NPC in Germany (2016-2027)
- Figure 15: Sub-type Specific Prevalence of NPC in Germany (2016-2027)
- Figure 16: Diagnosed Population of NPC in Germany (2016-2027)
- Figure 17: Clinical distribution of NPC by Phenotypes in Germany (2016-2027)
- Figure 18: Total Prevalent Population of NPC in France (2016-2027)
- Figure 19: Sub-type Specific Prevalence of NPC in France (2016-2027)
- Figure 20: Diagnosed Population of NPC in France (2016-2027)
- Figure 21: Clinical distribution of NPC by Phenotypes in France (2016-2027)
- Figure 22: Total Prevalent Population of NPC in Italy (2016-2027)
- Figure 23: Sub-type Specific Prevalence of NPC in Italy (2016-2027)
- Figure 24: Diagnosed Population of NPC in Italy (2016-2027)
- Figure 25: Clinical distribution of NPC by Phenotypes in Italy (2016-2027)
- Figure 26: Total Prevalent Population of NPC in Spain (2016-2027)
- Figure 27: Sub-type Specific Prevalence of NPC in Spain (2016-2027)
- Figure 28: Diagnosed Population of NPC in Spain (2016-2027)
- Figure 29: Clinical distribution of NPC by Phenotypes in Spain (2016-2027)
- Figure 30: Total Prevalent Population of NPC in the UK (2016-2027)
- Figure 31: Sub-type Specific Prevalence of NPC in the UK (2016-2027)
- Figure 32: Diagnosed Population of NPC in the United Kingdom (2016-2027)
- Figure 33: Clinical distribution of NPC by Phenotypes in the UK (2016-2027)
- Figure 34: Total Prevalent Population of NPC in Japan (2016-2027)
- Figure 35: Sub-type Specific Prevalence of NPC in Japan (2016-2027)



Figure 36: Diagnosed Population of NPC in Japan (2016-2027)

Figure 37: Clinical distribution of NPC by Phenotypes in Japan (2016-2027)

## I would like to order

Product name: Niemann-Pick Disease Type C (NPC) - Epidemiology Forecast to 2027

Product link: <https://marketpublishers.com/r/N3A5713F1F7EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N3A5713F1F7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970